Breaking news

Innate Pharma: positive data for monalizumab

Innate Pharma: positive data for monalizumab
Innate Pharma: positive data for monalizumab

(CercleFinance.com) – Innate Pharma announces that AstraZeneca presented this Friday the results of the randomized Phase 2 COAST trial at the annual meeting of the European Society for Medical Oncology (ESMO) on Innate’s monalizumab combination with durvalumab.

Interim analysis showed improvement in progression-free survival and objective response rate in patients with stage III, inoperable, non-small cell lung cancer compared to durvalumab as monotherapy.

On these results, AstraZeneca informed Innate of its intention to initiate a registration study with monalizumab in combination with durvalumab in patients with inoperable stage III non-small cell lung cancer.

Source

Innate Pharma positive data monalizumab

 
For Latest Updates Follow us on Google News
 

PREV Heineken sees its profit jump, but remains affected by the Covid
NEXT Oil delays, US crude stocks expected to rise